CONTE, PIETRO
 Distribuzione geografica
Continente #
EU - Europa 25
AS - Asia 23
NA - Nord America 17
Totale 65
Nazione #
CN - Cina 21
IT - Italia 19
US - Stati Uniti d'America 16
FR - Francia 2
VN - Vietnam 2
DE - Germania 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 65
Città #
Beijing 19
Trieste 10
Ashburn 3
Rome 3
Hanoi 2
Seattle 2
Amsterdam 1
Bellevue 1
Boardman 1
Bollate 1
Buffalo 1
Chicago 1
Ciudad Nicolás Romero 1
Los Angeles 1
Milan 1
Warsaw 1
Totale 49
Nome #
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial, file e2913fdf-457b-f688-e053-3705fe0a67e0 32
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET), file e2913fdf-155b-f688-e053-3705fe0a67e0 22
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial, file e2913fdb-63f7-f688-e053-3705fe0a67e0 6
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET), file e2913fdb-5fba-f688-e053-3705fe0a67e0 5
Totale 65
Categoria #
all - tutte 210
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 2 0 0 0 0
2020/20212 0 0 0 0 0 0 0 0 2 0 0 0
2021/20224 0 0 4 0 0 0 0 0 0 0 0 0
2022/202324 1 2 1 3 2 1 0 0 0 2 7 5
2023/202430 0 0 1 0 0 4 12 7 5 1 0 0
Totale 65